NCT03325595View on ClinicalTrials.gov

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

February 26, 2018

Study Completion Date

February 26, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

AEF0117

0.2, 0.6, 2, or 6mg of AEF0117

DRUG

Placebo

Matching capsule placebo

Trial Locations (1)

07103

Biotrial Inc, Newark

Sponsors

Lead Sponsor

Aelis Farma
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Aelis Farma

INDUSTRY

NCT03325595 - Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117 | Biotech Hunter | Biotech Hunter